论文部分内容阅读
对于卒中的一个重要的先兆征群——短暂性脑缺血发作(TIA)实施肝素治疗仍存争论。本文对46例TIAs病人接受肝素治疗发生出血并发症的危险性及临床结局进行了分析。 46例均符合脑血管病分类标准Ⅲ。大多数为严重TIAs或每周发作>2次。半数存在心脏病,但不包括瓣膜病、房颤、急性心梗或扩张型心肌病者。CT排除了出血,临床排除了舒张压>14.6kPa者。肝素通过静脉内滴注法给药,并行活化部分性促凝血酶原激酶时间(APTT)监测。肝素疗法的同时口服华法令。
There is controversy over the use of heparin in treating TIA, an important predictor of stroke. This article analyzed the risk of bleeding complications and clinical outcomes in 46 TIAs treated with heparin. 46 cases were consistent with cerebrovascular disease classification criteria Ⅲ. Most are severe TIAs or> 2 episodes per week. Half have heart disease but do not include valvular disease, atrial fibrillation, acute myocardial infarction, or dilated cardiomyopathy. CT ruled out bleeding, clinically excluded those with diastolic blood pressure> 14.6kPa. Heparin is administered by intravenous drip and parallel activated partial thromboplastin time (APTT) monitoring. Heparin therapy while oral warfarin.